

Nanoparticles as Nanomedicines

Marianne Ashford

AstraZeneca

Email: Marianne.Ashford@astrazeneca.com

Despite a huge amount of research into nanoparticles and many potential areas where the application of nanoparticles in medicine should enable innovative and important medicines there are relatively few products to date.

This talk will summarise some of the challenges in drug discovery and how potential applications of nanomedicines can address these. It will discuss some of the nanoparticles currently being explored as nanomedicines highlighting existing nanoparticles that have successfully been turned into products and emerging concepts currently being explored in clinical trials.

Accelerating the translation of nanomedicine is imperative to realise some of their potential. The talk will highlight some of the lessons learnt from Research & Development that can be applied to the translation of nanomedicines, and summarise some of the preclinical, formulation and analytical considerations required for nanomedicines that differ from traditional dosage forms